Tags

Type your tag names separated by a space and hit enter

Dietary equol and bone metabolism in postmenopausal Japanese women and osteoporotic mice.
J Nutr. 2010 Jul; 140(7):1373S-6S.JN

Abstract

Equol binds to the estrogen receptor with greater affinity than its precursor, daidzein, an isoflavone found in soybeans. Inter-individual differences in the ability to produce equol may lead to differential effects of isoflavone intervention on human health. Here, we review previously published work from our laboratory on equol producer status and bone health in humans and in a mouse model of osteoporosis. We performed a 1-y, double-blind, randomized trial to compare the effects of isoflavone (75 mg of isoflavone conjugates/d; equivalent to 47 mg/d of the aglycone form) with those of placebo on bone mineral density (BMD), fat mass, and serum isoflavone concentrations in 54 early postmenopausal Japanese women classified by their equol-producer phenotype. Isoflavone intervention increased the serum equol concentration in equol producers but not in nonproducers (P < 0.04). The annualized changes in BMD in the total hip and intertrochanteric regions in the isoflavone-treated equol producers (-0.46 and -0.04%, respectively) were less than in the nonproducers (-2.28 and -2.61%, respectively). The annualized change in fat mass was lower in the equol producers compared with the nonproducers in the isoflavone group. The annualized changes in BMD and fat mass did not differ between the equol producers and nonproducers in the placebo group. Equol also inhibited bone loss and fat accumulation in estrogen-deficient osteoporotic mice. Our data suggest that prevention of bone loss and fat accumulation in early postmenopausal women by isoflavones may depend on an individual's equol-producing capacity.

Authors+Show Affiliations

National Institute of Health and Nutrition, Tokyo 162-8636, Japan. ishimi@nih.go.jp

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20484547

Citation

Ishimi, Yoshiko. "Dietary Equol and Bone Metabolism in Postmenopausal Japanese Women and Osteoporotic Mice." The Journal of Nutrition, vol. 140, no. 7, 2010, 1373S-6S.
Ishimi Y. Dietary equol and bone metabolism in postmenopausal Japanese women and osteoporotic mice. J Nutr. 2010;140(7):1373S-6S.
Ishimi, Y. (2010). Dietary equol and bone metabolism in postmenopausal Japanese women and osteoporotic mice. The Journal of Nutrition, 140(7), 1373S-6S. https://doi.org/10.3945/jn.110.124842
Ishimi Y. Dietary Equol and Bone Metabolism in Postmenopausal Japanese Women and Osteoporotic Mice. J Nutr. 2010;140(7):1373S-6S. PubMed PMID: 20484547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dietary equol and bone metabolism in postmenopausal Japanese women and osteoporotic mice. A1 - Ishimi,Yoshiko, Y1 - 2010/05/19/ PY - 2010/5/21/entrez PY - 2010/5/21/pubmed PY - 2010/7/22/medline SP - 1373S EP - 6S JF - The Journal of nutrition JO - J Nutr VL - 140 IS - 7 N2 - Equol binds to the estrogen receptor with greater affinity than its precursor, daidzein, an isoflavone found in soybeans. Inter-individual differences in the ability to produce equol may lead to differential effects of isoflavone intervention on human health. Here, we review previously published work from our laboratory on equol producer status and bone health in humans and in a mouse model of osteoporosis. We performed a 1-y, double-blind, randomized trial to compare the effects of isoflavone (75 mg of isoflavone conjugates/d; equivalent to 47 mg/d of the aglycone form) with those of placebo on bone mineral density (BMD), fat mass, and serum isoflavone concentrations in 54 early postmenopausal Japanese women classified by their equol-producer phenotype. Isoflavone intervention increased the serum equol concentration in equol producers but not in nonproducers (P < 0.04). The annualized changes in BMD in the total hip and intertrochanteric regions in the isoflavone-treated equol producers (-0.46 and -0.04%, respectively) were less than in the nonproducers (-2.28 and -2.61%, respectively). The annualized change in fat mass was lower in the equol producers compared with the nonproducers in the isoflavone group. The annualized changes in BMD and fat mass did not differ between the equol producers and nonproducers in the placebo group. Equol also inhibited bone loss and fat accumulation in estrogen-deficient osteoporotic mice. Our data suggest that prevention of bone loss and fat accumulation in early postmenopausal women by isoflavones may depend on an individual's equol-producing capacity. SN - 1541-6100 UR - https://www.unboundmedicine.com/medline/citation/20484547/Dietary_equol_and_bone_metabolism_in_postmenopausal_Japanese_women_and_osteoporotic_mice_ L2 - https://academic.oup.com/jn/article-lookup/doi/10.3945/jn.110.124842 DB - PRIME DP - Unbound Medicine ER -